公开(公告)号：US11369690B2

公开(公告)日：2022-06-28

申请号：US16111250

申请日：2018-08-24

Applicant: ACADEMIA SINICA ,  KAOHSIUNG MEDICAL UNIVERSITY

Inventor： Steven R Roffler ,  Tian-Lu Cheng ,  Chien-Han Kao ,  Bing-Mae Chen ,  Yu-Cheng Su ,  Hsin-Yi Tung ,  Kuo-Hsiang Chuang

IPC: C07K16/00 ,  A61K39/00 ,  A61K47/68 ,  A61P35/00 ,  C07K16/32 ,  A61K39/395 ,  C07K16/28 ,  C07K16/26 ,  A61K47/14 ,  A61K47/69 ,  A61K45/06

Abstract: Disclosed herein is a bi-specific antibody that specifically directs a therapeutic agent to a cancer cell by targeting a tumor antigen of the cancer cell, and thereby suppressing the growth of the cancer or blocking the invasion or metastasis of the cancer. The bi-specific antibody of the present disclosure includes a first antigen binding site that binds to polyethylene glycol (PEG); and a second antigen binding site that binds to a target ligand, such as a tumor antigen.

公开(公告)号：US10188742B2

公开(公告)日：2019-01-29

申请号：US15123243

申请日：2015-03-02

Applicant: ACADEMIA SINICA ,  KAOHSIUNG MEDICAL UNIVERSITY

Inventor： Steven R Roffler ,  Tian-Lu Cheng ,  Chien-Han Kao ,  Bing-Mae Chen ,  Yu-Cheng Su ,  Hsin-Yi Tung ,  Kuo-Hsiang Chuang

IPC: C07K16/00 ,  A61K39/00 ,  A61K47/48 ,  A61K49/00 ,  C07K16/28 ,  C07K16/30 ,  C07K16/32 ,  C07K16/44 ,  A61K47/68

Abstract: Disclosed herein is a bi-specific antibody that specifically directs a therapeutic agent to a cancer cell by targeting a tumor antigen of the cancer cell, and thereby suppresses the growth of the cancer or blocking the invasion or metastasis of the cancer. The bi-specific antibody of the present disclosure includes a first antigen binding site that binds to polyethylene glycol (PEG); and a second antigen binding site that binds to a target ligand, such as a tumor antigen.

公开(公告)号：US20190022245A1

公开(公告)日：2019-01-24

申请号：US16111242

申请日：2018-08-24

Applicant: ACADEMIA SINICA ,  KAOHSIUNG MEDICAL UNIVERSITY

Inventor： STEVEN R ROFFLER ,  TIAN-LU CHENG ,  CHIEN-HAN KAO ,  BING-MAE CHEN ,  YU-CHENG SU ,  HSIN-YI TUNG ,  Kuo-Hsiang Chuang

IPC: A61K47/68 ,  C07K16/32 ,  A61K49/00 ,  C07K16/28 ,  C07K16/30 ,  C07K16/44

Abstract: Disclosed herein is a bi-specific antibody that specifically directs a therapeutic agent to a cancer cell by targeting a tumor antigen of the cancer cell, and thereby suppressing the growth of the cancer or blocking the invasion or metastasis of the cancer. The bi-specific antibody of the present disclosure includes a first antigen binding site that binds to polyethylene glycol (PEG); and a second antigen binding site that binds to a target ligand, such as a tumor antigen.

公开(公告)号：US11040111B2

公开(公告)日：2021-06-22

申请号：US16111242

申请日：2018-08-24

Applicant: ACADEMIA SINICA ,  KAOHSIUNG MEDICAL UNIVERSITY

Inventor： Steven R Roffler ,  Tian-Lu Cheng ,  Chien-Han Kao ,  Bing-Mae Chen ,  Yu-Cheng Su ,  Hsin-Yi Tung ,  Kuo-Hsiang Chuang

IPC: C07K16/00 ,  A61K47/68 ,  C07K16/44 ,  C07K16/32 ,  C07K16/30 ,  C07K16/28 ,  A61K49/00 ,  A61K47/69 ,  A61K39/395 ,  A61K47/60 ,  A61K39/00

Abstract: Disclosed herein is a bi-specific antibody that specifically directs a therapeutic agent to a cancer cell by targeting a tumor antigen of the cancer cell, and thereby suppressing the growth of the cancer or blocking the invasion or metastasis of the cancer. The bi-specific antibody of the present disclosure includes a first antigen binding site that binds to polyethylene glycol (PEG); and a second antigen binding site that binds to a target ligand, such as a tumor antigen.

公开(公告)号：US20210154319A9

公开(公告)日：2021-05-27

申请号：US16111242

申请日：2018-08-24

Applicant: ACADEMIA SINICA ,  KAOHSIUNG MEDICAL UNIVERSITY

Inventor： STEVEN R ROFFLER ,  TIAN-LU CHENG ,  CHIEN-HAN KAO ,  BING-MAE CHEN ,  YU-CHENG SU ,  HSIN-YI TUNG ,  Kuo-Hsiang Chuang

IPC: A61K47/68 ,  C07K16/32 ,  A61K49/00 ,  C07K16/28 ,  C07K16/30 ,  C07K16/44

Abstract: Disclosed herein is a bi-specific antibody that specifically directs a therapeutic agent to a cancer cell by targeting a tumor antigen of the cancer cell, and thereby suppressing the growth of the cancer or blocking the invasion or metastasis of the cancer. The bi-specific antibody of the present disclosure includes a first antigen binding site that binds to polyethylene glycol (PEG); and a second antigen binding site that binds to a target ligand, such as a tumor antigen.

公开(公告)号：US20170056523A1

公开(公告)日：2017-03-02

申请号：US15123243

申请日：2015-03-02

Applicant: ACADEMIA SINICA ,  KAOHSIUNG MEDICAL UNIVERSITY

Inventor： STEVEN R ROFFLER ,  TIAN-LU CHENG ,  CHIEN-HAN KAO ,  BING-MAE CHEN ,  YU-CHENG SU ,  HSIN-YI TUNG ,  Kuo-Hsiang Chuang

IPC: A61K47/48 ,  A61K49/00 ,  C07K16/28 ,  C07K16/32 ,  C07K16/44 ,  C07K16/30

CPC classification number: A61K47/6879 ,  A61K47/6897 ,  A61K49/0002 ,  C07K16/2803 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/30 ,  C07K16/3061 ,  C07K16/32 ,  C07K16/44 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/622 ,  C07K2317/624 ,  C07K2317/73

Abstract: Disclosed herein is a bi-specific antibody that specifically directs a therapeutic agent to a cancer cell by targeting a tumor antigen of the cancer cell, and thereby suppresses the growth of the cancer or blocking the invasion or metastasis of the cancer. The bi-specific antibody of the present disclosure includes a first antigen binding site that binds to polyethylene glycol (PEG); and a second antigen binding site that binds to a target ligand, such as a tumor antigen.

Abstract translation: 本文公开了通过靶向癌细胞的肿瘤抗原来特异性地将治疗剂引导至癌细胞的双特异性抗体，从而抑制癌症的生长或阻断癌症的侵袭或转移。 本公开的双特异性抗体包括结合聚乙二醇（PEG）的第一抗原结合位点; 以及结合靶配体例如肿瘤抗原的第二抗原结合位点。

公开(公告)号：US09329180B2

公开(公告)日：2016-05-03

申请号：US14057999

申请日：2013-10-18

Applicant: KAOHSIUNG MEDICAL UNIVERSITY

Inventor： Tian-Lu Cheng ,  Steven R. Roffler ,  Kuo-Hsiang Chuang ,  Ssu-Jung Lu

IPC: G01N33/53 ,  G01N33/554 ,  G01N33/68 ,  G01N33/94 ,  C07K16/44

CPC classification number: G01N33/554 ,  C07K16/44 ,  C07K2317/56 ,  C07K2319/03 ,  C12N2503/02 ,  C12N2510/04 ,  G01N33/5308 ,  G01N33/6857 ,  G01N33/94 ,  G01N33/9493 ,  G01N2430/60 ,  G01N2440/28

Abstract: The present invention provides a method for preparing an isolated eukaryotic cell which presents an anti-polyethylene glycol (PEG) antibody on a cell membrane. The present invention also provides a method for a quantitative analysis of a polyethylene glycol (PEG) by said anti-PEG antibody expressing cell. The cell-based quantitative analysis of the present prevention could sensitively quantify free PEG and PEG-modified macromolecules (proteins, nanoparticles and liposomes) as sensitive as nano-gram level.

Abstract translation: 本发明提供了一种在细胞膜上提供抗聚乙二醇（PEG）抗体的分离的真核细胞的制备方法。 本发明还提供了通过所述抗-PEG抗体表达细胞定量分析聚乙二醇（PEG）的方法。 本发明预防的基于细胞的定量分析可以灵敏地定量游离的PEG和PEG修饰的大分子（蛋白质，纳米颗粒和脂质体）作为纳克级水平敏感。

公开(公告)号：US20210292438A1

公开(公告)日：2021-09-23

申请号：US17340102

申请日：2021-06-07

Applicant: ACADEMIA SINICA

Inventor： Steve ROFFLER ,  Tian-Lu Cheng ,  Yu-Cheng Su ,  Kuo-Hsiang Chuang

IPC: C07K16/44 ,  A61K47/60 ,  A61K47/69 ,  A61P35/00 ,  A61K31/55 ,  A61K31/704 ,  A61K51/06 ,  C07K16/28 ,  C07K16/30 ,  C07K16/32 ,  G01N33/574

Abstract: A monomeric bispecific polyethylene glycol (PEG) engager that includes an anti-PEG Fab fused to a disulfide stabilized scFv that specifically binds to a cell surface antigen. The PEG engager, in the absence of PEG, remains monomeric upon binding to the cell surface antigen on a cell and remains on the surface of the cell. Also disclosed is a method for treating cancer by administering a PEG engager followed by a PEGylated anti-cancer agent. Further disclosed is a method for diagnosing a cell-mediated disorder by administering a PEG engager followed by a PEGylated diagnostic agent.